PMID- 30854928
OWN - NLM
STAT- MEDLINE
DCOM- 20190911
LR  - 20220408
IS  - 1724-6008 (Electronic)
IS  - 0393-6155 (Linking)
VI  - 34
IP  - 1
DP  - 2019 Mar
TI  - beta-Arrestin-1 expression and epithelial-to-mesenchymal transition in laryngeal 
      carcinoma.
PG  - 33-40
LID - 10.1177/1724600818813621 [doi]
AB  - AIM: The novel primary end-point of the present study was to ascertain 
      beta-arrestin-1 expression in a cohort of consecutive patients with laryngeal 
      squamous cell carcinoma (LSCC) with information available on their 
      cigarette-smoking habits. A secondary end-point was to conduct a preliminary 
      clinical and pathological investigation into the possible role of beta-arrestin-1 in 
      the epithelial-to-mesenchymal transition (EMT), identified by testing for 
      E-cadherin, Zeb1, and Zeb2 expression, in the setting of LSCC. METHODS: The 
      expression of beta-arrestin-1, E-cadherin, zeb1, and zeb2 was ascertained in 20 
      consecutive LSCCs. RESULTS: Statistical analysis showed no significant 
      associations between beta-arrestin-1 and EMT (based on the expression of E-cadherin, 
      Zeb1, and Zeb2). The combined effect of nicotine and beta-arrestin-1 was 
      significantly associated with a shorter disease-free survival ( P=0.01) in our 
      series of LSCC. This latter result was also confirmed in an independent, publicly 
      available LSCC cohort ( P=0.047). CONCLUSIONS: Further investigations on larger 
      series (ideally in prospective settings) are needed before we can consider closer 
      follow-up protocols and/or more aggressive treatments for patients with LSCC and 
      a combination of nicotine exposure and beta-arrestin-1 positivity in tumor cells at 
      the time of their diagnosis. Further studies on how beta-arrestin functions in 
      cancer via different signaling pathways might reveal potential targets for the 
      treatment of even advanced laryngeal malignancies.
FAU - Marioni, Gino
AU  - Marioni G
AD  - 1 Department of Neuroscience DNS, Otolaryngology Section, Padova University, 
      Padova, Italy.
FAU - Nicole, Lorenzo
AU  - Nicole L
AD  - 2 Department of Medicine DIMED, University of Padova, Italy.
FAU - Cappellesso, Rocco
AU  - Cappellesso R
AD  - 2 Department of Medicine DIMED, University of Padova, Italy.
FAU - Marchese-Ragona, Rosario
AU  - Marchese-Ragona R
AD  - 1 Department of Neuroscience DNS, Otolaryngology Section, Padova University, 
      Padova, Italy.
FAU - Fasanaro, Elena
AU  - Fasanaro E
AD  - 3 Radiotherapy Unit, Istituto Oncologico Veneto, IOV-IRCSS, Padova, Italy.
FAU - Di Carlo, Roberto
AU  - Di Carlo R
AD  - 1 Department of Neuroscience DNS, Otolaryngology Section, Padova University, 
      Padova, Italy.
FAU - La Torre, Fabio Biagio
AU  - La Torre FB
AD  - 4 Otolaryngology Unit, Azienda Ospedaliera "S. Maria degli Angeli," Pordenone, 
      Italy.
FAU - Nardello, Ennio
AU  - Nardello E
AD  - 1 Department of Neuroscience DNS, Otolaryngology Section, Padova University, 
      Padova, Italy.
FAU - Sanavia, Tiziana
AU  - Sanavia T
AD  - 5 Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
FAU - Ottaviano, Giancarlo
AU  - Ottaviano G
AD  - 1 Department of Neuroscience DNS, Otolaryngology Section, Padova University, 
      Padova, Italy.
FAU - Fassina, Ambrogio
AU  - Fassina A
AD  - 2 Department of Medicine DIMED, University of Padova, Italy.
LA  - eng
PT  - Journal Article
DEP - 20190310
PL  - United States
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDH1 protein, human)
RN  - 0 (Cadherins)
RN  - 0 (ZEB1 protein, human)
RN  - 0 (ZEB2 protein, human)
RN  - 0 (Zinc Finger E-box Binding Homeobox 2)
RN  - 0 (Zinc Finger E-box-Binding Homeobox 1)
RN  - 0 (beta-Arrestin 1)
SB  - IM
MH  - Aged
MH  - Antigens, CD/metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Cadherins/metabolism
MH  - Carcinoma, Squamous Cell/metabolism/*pathology
MH  - *Epithelial-Mesenchymal Transition
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Laryngeal Neoplasms/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Rate
MH  - Zinc Finger E-box Binding Homeobox 2/metabolism
MH  - Zinc Finger E-box-Binding Homeobox 1/metabolism
MH  - beta-Arrestin 1/*metabolism
OTO - NOTNLM
OT  - Laryngeal carcinoma
OT  - epithelial-to-mesenchymal transition
OT  - nicotine
OT  - prognosis
OT  - beta-arrestin-1
EDAT- 2019/03/12 06:00
MHDA- 2019/09/12 06:00
CRDT- 2019/03/12 06:00
PHST- 2019/03/12 06:00 [pubmed]
PHST- 2019/09/12 06:00 [medline]
PHST- 2019/03/12 06:00 [entrez]
AID - 10.1177/1724600818813621 [doi]
PST - ppublish
SO  - Int J Biol Markers. 2019 Mar;34(1):33-40. doi: 10.1177/1724600818813621. Epub 
      2019 Mar 10.